Geron Corp Reports Third Quarter 2026 Profitability Driven by RYTELO Growth
Geron Corporation (GERN) achieved its first profitable quarter since transitioning to a commercial-stage biopharmaceutical company, reporting net income of $1.4 million for Q3 2026. This turnaround was driven by a 27% year-over-year increase in net product revenue, totaling $60.1 million, and significant reductions in operating expenses following previous workforce optimizations. The company's RYTELO product saw steady adoption, with prescribing accounts growing to approximately 1,700. While the company issued positive full-year revenue guidance of $220 million to $240 million, it also noted the discontinuation of its Phase III IMpactMF trial due to an inability to meet primary endpoints regarding overall survival in relapsed/refractory myelofibrosis patients.
Tickers: $GERN
Topics: financial guidance net income product demand revenue growth
Read the full article at Motley Fool
Part of the story Geron Corp Reports Third Quarter 2026 Profitability Driven by RYTELO Growth (15 articles)